Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market moves: The S & P 500 was slightly higher to start the week, but most of the gains were concentrated in AI-related technology stocks and the Magnificent Seven — especially Amazon, after it struck a multiyear deal with OpenAI worth $38 billion of compute capacity. The Nasdaq , with a heavier weighting in tech, was modestly higher. The rally in most of the Mag 7, which included Nvidia on a host of positive developments , came as if on cue after Jim Cramer’s Sunday column about not judging the stocks by their outsized portion of the overall market but as individual stories with long runways of growth ahead. Spin housekeeping: Now that the Honeywell -Solstice and DuPont -Qnity Electronics splits are complete, we need to revise our price targets on the two former parent companies to reflect the loss of value from the spins and introduce new price targets on Solstice and Qnity. We plan to make those changes in the coming days. We will have a better idea after DuPont and Solstice report Thursday morning and Qnity provides its business update Thursday evening. But to give you a sense of how we are thinking about Qnity, five major firms have launched coverage on this semiconductor materials maker with buy or buy-equivalent ratings and an average price target of about $113. That is our favorite. Solstice trading is going to be volatile over the next few weeks as its shareholder base turns over from multi-industry and aerospace-minded investors toward chemicals. But there are interesting, secular growing parts to the company, especially on the nuclear energy side. UBS initiated Solstice with a buy and $62 price target on Monday, but we want to see how management guides. Remember, the remaining Honeywell, which is made up of automation and aerospace, will split into two separate companies in the second half of next year. Lilly rally: Eli Lilly ‘s post-earnings rally was powering ahead for a third session in a row. With Monday’s roughly 3% gain, the stock is now up roughly 9% since the drugmaker’s beat and raise third quarter earnings report last Thursday. The move back to the upper $800s puts the stock at its highest levels since its first quarter 2025 earnings report . Shares plunged 11% that day, falling from $898 to $794, after news that Novo Nordisk had struck a deal with CVS Caremark to make Wegovy, the preferred GLP-1 weight loss drug for patients. But as we learned from Lilly’s earnings call last week, the impact has not nearly been as bad as feared. The Lilly news Monday is that it is planning to build a $3 billion manufacturing facility in the Netherlands. The plant is expected to expand Lilly’s oral medicines, including its GLP-1 orforglipron, and strengthen the company’s global supply chain. Lilly is investing tens of billions of dollars to expand its manufacturing footprint in the U.S. and overseas, which we see as a strong vote of confidence in both its current portfolio and future launches. Up next: Palantir, Him’s & Hers, Goodyear Tire, Clorox, Coterra Energy, and Diamondback Energy report earnings after Monday’s closing bell. On Tuesday morning, we get earnings from Eaton , Pfizer, Shopify, Uber, Spotify, Ferrari, and Norwegian Cruise Line. (See here for a full list of the stocks in Jim Cramer’s Charitable Trust, including AMZN, NVDA, HON, SOLS, DD, Q, LLY, ETN.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Sunday, February 15
Tech rules Monday’s stock market — plus, Eli Lilly’s big comeback
Risk Disclosure and Disclaimer for PropFirmFinance.com
Trading financial instruments, including forex, stocks, commodities, and cryptocurrencies, involves a high level of risk and may not be suitable for all investors. The value of financial instruments can fluctuate significantly due to market volatility, economic events, regulatory actions, or political developments. You may sustain a loss of some or all of your invested capital. Trading on margin or using leverage can further amplify losses and increase your financial exposure.
Before engaging in any trading activity, carefully assess your investment goals, level of experience, and risk appetite. It is strongly recommended to seek advice from a licensed financial advisor if you are uncertain about the risks involved.
PropFirmFinance.com provides content for informational and educational purposes only. While we strive to offer accurate, timely, and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any data presented on this website. Market data, prices, charts, and signals may not always be real-time or sourced from official exchanges. Such information is provided on an “as-is” basis and should not be used for trading or investment decisions.
PropFirmFinance.com, its owners, contributors, and partners shall not be held responsible for any losses or damages incurred as a result of using the information provided on this website. Users assume full responsibility for their trading actions and outcomes.
All content on this site, including data, text, graphics, and logos, is protected by applicable intellectual property laws. Any reproduction, redistribution, or unauthorized use of material from this website is strictly prohibited without prior written consent.
We may receive compensation from partners and advertisers featured on this website. Compensation may influence the placement or visibility of certain content but does not affect our editorial integrity or objectivity.
By using this website, you acknowledge and agree to the terms of this disclaimer.
© 2026 propfirmfinance.com.